Lee Biosolutions Announces Availability of Eosinophil Cationic Protein

Published: Sep 5th, 2006

September 5, 2006; ST. LOUIS Eosinophil cationic protein derived from human neutrophils is now available to the clinical research community from Lee Biosolutions, at LeeBio.com.

Eosinophils are granulocytes that commonly increase in number in the presence of parasites and allergies. Clinical researchers continue to explore methods for using eosinophil in the pathogenesis of a variety of illnesses, including respiratory conditions such as asthma, nasal polyposis and allergic rhinitis.

According to Lee Biosolutions President Burton Lee, the company plans to also have a polyclonal eosinophil cationic protein antibody available for Fall 2006.

We are expanding our product line almost daily to meet todays needs and tomorrows trends in research, Lee said. We strive to anticipate customers needs ahead of time so when theyre ready, we can provide the products they need as a source they already trust for purity and consistency.

Eosinophils comprise roughly 1% to 4% of the blood?s cellular make-up. The cells are active in allergic diseases, parasitic infections, and other disorders.

For over 30 years, Lee Biosolutions has been providing proteins, enzymes and other materials to research facilities around the country that work to advance the healthcare industry. By providing Solutions on Demand, Lee Biosolutions has become the preferred source for materials such as myeloperoxidase (MPO) and renin.

Lee Biosolutions is a leader in the biomaterials industry, providing quality biomaterial products to clinical labs and researchers around the world, developing tomorrows cures. Leebio has provided human proteins used in a number of high profile biomarker studies. For more information or to place an order,contact:

Lee Biosolutions, Inc
2924 Mary Ave
St. Louis, MO 63144
Tel:314-968-1091
www.leebio.com